Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02614066 · ClinicalTrials.gov registry record · Phase 1
A Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel (KTE-X19) in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ZUMA-3)
A Phase 1 study, sponsored by Kite, A Gilead Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 125
- Enrollment target
NCT02614066 is a Phase 1 study that has completed, run by Kite, A Gilead Company. The registered enrollment target is 125 participants.
The verdict
NCT02614066, a Phase 1 study, has completed, sponsored by Kite, A Gilead Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 125 participants
- Enrollment target
Study Summary
The primary objectives of this study are to determine the safety and efficacy of brexucabtagene autoleucel (KTE-X19) in adult participants with relapsed/refractory (r/r) B-precursor acute lymphoblastic leukemia (ALL).
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- BIOLOGICAL brexucabtagene autoleucel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2016-03-07 |
| Est. Completion | 2023-11-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02614066
The ClinicalTrials.gov registry entry for NCT02614066 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 125 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kite, A Gilead Company, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cyclophosphamide is the first listed.
NCT02614066 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02614066 about?
NCT02614066 is a clinical study titled "A Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel (KTE-X19) in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ZUMA-3)". The primary objectives of this study are to determine the safety and efficacy of brexucabtagene autoleucel (KTE-X19) in adult participants with relapsed/refractory (r/r) B-precursor acute lymphoblastic leukemia (ALL).
What is the current status of trial NCT02614066?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 125 participants. The study started on 2016-03-07. Estimated completion is 2023-11-03.
What interventions are being tested in trial NCT02614066?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), brexucabtagene autoleucel (BIOLOGICAL).
Who is sponsoring clinical trial NCT02614066?
This trial is sponsored by Kite, A Gilead Company, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.